Frank Frantzen
Director Técnico/Científico/I+D en CardiNor AS .
Perfil
Frank Frantzen is currently the Chief Technology Officer at CardiNor AS.
Prior to this, he worked as the Senior Director of Research and Development at Abbott Norge AS and as a Director at Gentian Diagnostics ASA. Frantzen holds a graduate and doctorate degree from the Norwegian University of Science & Technology.
Cargos activos de Frank Frantzen
| Empresas | Cargo | Inicio |
|---|---|---|
CardiNor AS
 CardiNor AS BiotechnologyHealth Technology CardiNor AS develops, produces, and sells in-vitro diagnostic products. It establishes a blood test for elevated levels of Secretoneurin that may indicate that a patient has a heart disease. The company was founded on June 25, 2015 and is headquartered in Oslo, Norway. | Director Técnico/Científico/I+D | - |
Antiguos cargos conocidos de Frank Frantzen.
| Empresas | Cargo | Fin |
|---|---|---|
| GENTIAN DIAGNOSTICS | Director/Miembro de la Junta | 18/12/2023 |
Abbott Norge AS
 Abbott Norge AS Pharmaceuticals: MajorHealth Technology Abbott Norge AS researches, markets, and trades pharmaceuticals and laboratory diagnostics. The company was founded on March 12, 1990 and is headquartered in Fornebu, Norway. | Director Técnico/Científico/I+D | 01/01/2021 |
Formación de Frank Frantzen.
| Norwegian University of Science & Technology | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| GENTIAN DIAGNOSTICS | Health Technology |
| Empresas privadas | 2 |
|---|---|
Abbott Norge AS
Abbott Norge AS Pharmaceuticals: MajorHealth Technology Abbott Norge AS researches, markets, and trades pharmaceuticals and laboratory diagnostics. The company was founded on March 12, 1990 and is headquartered in Fornebu, Norway. | Health Technology |
CardiNor AS
CardiNor AS BiotechnologyHealth Technology CardiNor AS develops, produces, and sells in-vitro diagnostic products. It establishes a blood test for elevated levels of Secretoneurin that may indicate that a patient has a heart disease. The company was founded on June 25, 2015 and is headquartered in Oslo, Norway. | Health Technology |
- Bolsa de valores
- Insiders
- Frank Frantzen
